Abstract
Ataxia telangiectasia-mutated and Rad3-related (ATR) protein kinase is an attractive anticancer target. In this study, comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) were performed on a series of aminopyrazine ATR inhibitors. The models generated by CoMFA had a cross-validated coefficient (q2) of 0.752 and a regression coefficient (r2) of 0.947. The CoMSIA models had a q2 of 0.728 and an r2 of 0.936. The reasonable quantitative structure-activity relationship model showed robust predictive ability. The contour map provided guidelines for building novel virtual compounds based on compound NO.40. In addition, the 3D structure of ATR was modeled by homology modeling. Molecular dynamic simulations were employed to optimize the structure. The docking results offered insights into the interactions between the inhibitors and the active site for potent analysis. This study provides useful guidance for the discovery of more potent compounds.
Keywords: ATR inhibitor, 3D-QSAR, CoMFA, CoMSIA, docking, homology modeling, molecular design.
Current Computer-Aided Drug Design
Title:3D-QSAR Analysis on ATR Protein Kinase Inhibitors Using CoMFA and CoMSIA
Volume: 10 Issue: 4
Author(s): Xiurong Li, Mao Shu, Yuanqiang Wang, Rui Yu, Shuang Yao and Zhihua Lin
Affiliation:
Keywords: ATR inhibitor, 3D-QSAR, CoMFA, CoMSIA, docking, homology modeling, molecular design.
Abstract: Ataxia telangiectasia-mutated and Rad3-related (ATR) protein kinase is an attractive anticancer target. In this study, comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) were performed on a series of aminopyrazine ATR inhibitors. The models generated by CoMFA had a cross-validated coefficient (q2) of 0.752 and a regression coefficient (r2) of 0.947. The CoMSIA models had a q2 of 0.728 and an r2 of 0.936. The reasonable quantitative structure-activity relationship model showed robust predictive ability. The contour map provided guidelines for building novel virtual compounds based on compound NO.40. In addition, the 3D structure of ATR was modeled by homology modeling. Molecular dynamic simulations were employed to optimize the structure. The docking results offered insights into the interactions between the inhibitors and the active site for potent analysis. This study provides useful guidance for the discovery of more potent compounds.
Export Options
About this article
Cite this article as:
Li Xiurong, Shu Mao, Wang Yuanqiang, Yu Rui, Yao Shuang and Lin Zhihua, 3D-QSAR Analysis on ATR Protein Kinase Inhibitors Using CoMFA and CoMSIA, Current Computer-Aided Drug Design 2014; 10 (4) . https://dx.doi.org/10.2174/1573409910666140701094853
DOI https://dx.doi.org/10.2174/1573409910666140701094853 |
Print ISSN 1573-4099 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6697 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 EnzymesMolecular Mechanisms Regulating the Mitochondrial Targeting of Microsomal Cytochrome P450 Enzymes
Current Drug Metabolism Coinage Metal Complexes Against Breast Cancer
Current Medicinal Chemistry Protein Kinase C and Prostate Carcinogenesis: Targeting the Cell Cycle and Apoptotic Mechanisms
Current Drug Targets Editorial [Hot Topic: Choosing between Targeted Therapies for Rheumatoid Arthritis Patients (Guest Editor: Filip De Keyser)]
Current Rheumatology Reviews Pharmacogenomic Approaches to Osteoporosis: 2005 Update
Current Pharmacogenomics Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry D1 and Functionally Selective Dopamine Agonists as Neuroprotective Agents in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Dual Functional Small Molecule Probes as Fluorophore and Ligand for Misfolding Proteins
Current Organic Chemistry Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery 64Cu Labeled AmBaSar-RGD2 for micro-PET Imaging of Integrin αvβ3 Expression
Current Radiopharmaceuticals Strategies for the Design of Selective Protein Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Dimensional Assessment of Hypochondriacal Fears and Beliefs
Current Psychiatry Reviews Augmenting T Helper Cell Immunity in Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy
Current Pharmaceutical Design Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Current Drug Targets Design, Synthesis and Antibacterial Evaluation of Compounds Based on New Benzoxepine-oxime-1,2,3-triazole Hybrid
Mini-Reviews in Medicinal Chemistry IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Mechanisms of Microcystin-induced Cytotoxicity and Apoptosis
Mini-Reviews in Medicinal Chemistry In-Silico Algorithms for the Screening of Possible microRNA Binding Sites and Their Interactions
Current Genomics Linking Inflammation to Cell Cycle Progression
Current Pharmaceutical Design